



## New Clinical Study on TOUCH® CMC 1 Prosthesis Enrolls First Patient

(June 8, 2026 – Warsaw, Indiana) KeriMedical (Medartis Group) has officially launched the first clinical study of the TOUCH® CMC 1 Prosthesis in a U.S. patient population ([NCT #7405983](#)). Dr. F. Thomas D. Kaplan, assisted by Dr. Brandon Smetana, enrolled the first patient on March 23<sup>rd</sup> at [Indiana Hand to Shoulder Center](#), an OrthoIndy practice, in Indianapolis. This is the first in a 163-patient post-approval study commitment to the FDA. Patients will be followed for a minimum of two years to observe the rate of pain reduction and functional improvement.

TOUCH® CMC 1 Prosthesis is intended for first carpometacarpal (CMC) primary total joint arthroplasty in patients with symptomatic Eaton-Littler Stage II or III osteoarthritis. FDA approval ([PMA 240020](#)) of this cementless, dual-mobility total CMC prosthesis was supported by a body of clinical evidence established over a decade of market presence in Europe.

“We are excited to help launch the first US study that will provide insight into the benefits of total joint replacement for patients suffering from debilitating thumb arthritis. Our patients deserve a better option that may provide quicker recovery and better strength than traditional surgery. This study has the potential to pave the way for a paradigm shift in how US surgeons treat thumb arthritis - just as hip replacement surgery did decades ago.” – F. Thomas D. Kaplan MD, fellowship director at Indiana Hand to Shoulder Center

“This first patient inclusion marks an important milestone in our post approval study, conducted in accordance with FDA requirements. Through the collaboration with MCRA, an IQVIA business, and medical centers experienced in clinical studies, KeriMedical is committed to ensuring the quality of this study. We hope this will be a first step towards scientific research on the TOUCH® CMC 1 Prosthesis in the United States.” – Déborah Caux, Clinical Affairs Manager, KeriMedical SA, a Medartis Group company

“We thank the study team and forthcoming patients for their contribution to US clinical evidence related to first carpometacarpal total joint arthroplasty with TOUCH® CMC 1 Prosthesis,” stated Charles Florek PhD, Director of Clinical Research for Medartis Inc.

TOUCH® CMC 1 Prosthesis is commercially available in the United States, [PMA 240020](#). Study enrollment is not a requirement for surgery. A trained surgeon can let you know if you are a qualified candidate for first CMC total joint arthroplasty.



- END -

---

**Media Contact:**

Medartis US Corporate Communications  
Dave Temple, Executive Director of Marketing Communications  
Email: [us\\_corporate\\_communications@medartis.com](mailto:us_corporate_communications@medartis.com)  
Phone: +1 574 376 2404

**About Medartis**

Founded in 1997 and headquartered in Basel, Switzerland, the Medartis Group is one of the world's leading manufacturers and providers of medical devices for surgical fixation of bone fractures and joint replacement for upper and lower extremities as well as for the craniomaxillofacial region. The Group has manufacturing sites in the United States, Switzerland, Brazil and France. Medartis employs approx. 1,400 individuals across its 13 locations, with products offered in over 50 countries globally. Medartis is committed to providing surgeons and operating theatre personnel with the most innovative implants and instruments as well as best-in-class service.

For more information, please visit [www.medartisusa.com](http://www.medartisusa.com).

**About Keri Medical**

Founded in 2016, Keri Medical, a Medartis Group company, specializes in developing and marketing a comprehensive range of implants exclusively for hand & wrist surgery. The Keri Medical team possesses extensive experience in orthopaedic surgery with expertise across all operational areas: design, manufacturing, quality, marketing and product promotion. Keri Medical collaborates with a panel of surgeons who have recognized expertise in France and internationally. These specialists share their clinical and medical knowledge to support the development and validation of new solutions. The company is headquartered in Geneva, employs approx. 150 employees and its products are available in 30 countries. For further information, please visit [www.kerimedical.com](http://www.kerimedical.com).

**About Indiana Hand to Shoulder Center, an OrthoIndy practice**

Indiana Hand to Shoulder Center, an OrthoIndy practice, is recognized worldwide for its specialization in the treatment of upper extremity injuries and disorders. For over 50 years, its physicians have advanced patient care through a unique combination of specialized clinical expertise, academic training and innovation. The practice is home to one of the country's most respected hand and upper extremity fellowship programs, training surgeons from across the U.S., and maintains a strong tradition of clinical research, with physicians publishing in and serving as editors for leading academic journals. Indiana Hand to Shoulder Center also operates a comprehensive Nerve Injury and Limb Pain Program, providing state of the art care for patients with complex nerve injuries, as well as one of the largest therapy facilities in the nation dedicated to upper extremity rehabilitation. Learn more at [indianahandtoshoulder.com](http://indianahandtoshoulder.com).